Key result
Ramipril lowered the risk of atherosclerotic disease events and death, whereas vitamin E (400 IU/day for 4.5 years) did not significantly lower risk.
Why the study?
Does ramipril or vitamin E reduce atherosclerotic disease events and death in patients without heart failure but with known atherosclerosis or diabetes plus at least one cardiovascular risk factor?
Does ramipril or vitamin E reduce atherosclerotic disease events and death in patients without heart failure but with known atherosclerosis or diabetes plus at least one cardiovascular risk factor?
Ramipril reduces the risk of atherosclerotic events and death in high-risk patients without heart failure, while vitamin E supplementation shows no significant cardiovascular benefit.
No takes yet. Share an insight, caveat, or question.
May support ramipril in high-risk patients without HF; leaves open vitamin E's role in atherosclerosis prevention.
Hoogwerf et al. (2000) conducted a review in Atherosclerosis or diabetes with cardiovascular risk factors. Ramipril and Vitamin E was evaluated on Atherosclerotic disease events and death. Ramipril lowered the risk of atherosclerotic disease events and death, whereas vitamin E (400 IU/day for 4.5 years) did not significantly lower risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: